{
  "id": "640ddd9d201352f04a000028",
  "type": "list",
  "question": "What were the first 2 PD-1 inhibitors approved by the FDA in 2014?",
  "ideal_answer": "The first two PD-1 inhibitors approved by the FDA in 2014 were nivolumab (Opdivo) and pembrolizumab (Keytruda).",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/33686894",
    "http://www.ncbi.nlm.nih.gov/pubmed/25682878",
    "http://www.ncbi.nlm.nih.gov/pubmed/29222273",
    "http://www.ncbi.nlm.nih.gov/pubmed/30304963",
    "http://www.ncbi.nlm.nih.gov/pubmed/27795534",
    "http://www.ncbi.nlm.nih.gov/pubmed/26822752",
    "http://www.ncbi.nlm.nih.gov/pubmed/27058852",
    "http://www.ncbi.nlm.nih.gov/pubmed/32388240",
    "http://www.ncbi.nlm.nih.gov/pubmed/29357948",
    "http://www.ncbi.nlm.nih.gov/pubmed/32984529",
    "http://www.ncbi.nlm.nih.gov/pubmed/28923211"
  ],
  "snippets": [
    {
      "text": "2 different programmed cell death protein 1 (PD-1) inhibitors, Nivolumab and Pembrolizumab.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32984529",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The first monoclonal antibodies against the immune checkpoint programmed death 1 (PD-1) receptor, nivolumab and pembrolizumab, are now approved for clinical use",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26822752",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "e programmed cell death protein 1 (PD-1) inhibitors, nivolumab and pembrolizumab, have quickly been incorporated into clinical trials for first- and second-line therapy of Hodgkin lymphoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29222273",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The first programmed death 1 (PD-1) inhibitor, pembrolizumab, was recently approved by the United States Food and Drug Administration for the treatment of melanoma; nivolumab was previously approved in Japan. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25682878",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Early-phase studies investigating several humanized monoclonal IgG4 antibodies targeting PD-1 and PD-L1 in advanced solid tumors paved way for the development of the first PD-1 inhibitors, nivolumab and pembrolizumab, approved by the Food and Drug Administration (FDA) in 2014.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29357948",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Nivolumab (Opdivo, Bristol Meyer Squibb, New York, NY) and pembrolizumab (Keytruda, Merck, Kenilworth, NJ) are the first two US Food and Drug Administration (FDA)-approved monoclonal antibodies targeting programmed death-1 (PD-1).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28923211",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The US Food and Drug Administration (FDA) has approved 2 PD-1 inhibitors, nivolumab and pembrolizumab, and several others are under investigation.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27058852",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The first programmed death 1 (PD-1) inhibitor, pembrolizumab, was recently approved by the United States Food and Drug Administration for the treatment of melanoma; nivolumab was previously approved in Japan.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25682878",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "other tumors. In 2014, nivolumab and pembrolizumab, two checkpoint inhibitors binding to PD-1, were approved for the treatment of metast",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33686894",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " Pembrolizumab is one of the first immune checkpoint inhibitors approved by the FDA to treat NSCLC and is currently the only immunotherapy drug approved for first-line treatment of NSCLC in immune checkpoint inhibitors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32388240",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " A PD-1 antibody, nivolumab, was the first of these agents to be approved by the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan, as a new cancer drug for melanoma, in July 2014.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27795534",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "s paved way for the development of the first PD-1 inhibitors, nivolumab and pembrolizumab, approved by the Food and Drug Administration (FDA) in 2014.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29357948",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ministration (FDA) approved the first PD-1 targeting agent, namely pembrolizumab, shortly followed by nivolumab. Areas covered: Nivolumab is a fully h",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30304963",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Pembrolizumab, Keytruda, Nivolumab, Opdivo"
}